Forecasts data is unavailable for this security.
Consensus recommendation
- 14-Sep-23
- 20-Jun-24
- 18-Jul-24
- 15-Aug-24
- 12-Sep-24
Select bar for recommendation details.
Recommendations | 12-Sep-24 | |
---|---|---|
Buy | 9 | |
Outperform | 14 | |
Hold | 4 | |
Sell | 0 | |
Strong Sell | 0 |
Share price forecast in USD
The 23 analysts offering 12 month price targets for Neurocrine Biosciences, Inc. have a median target of 170.00, with a high estimate of 204.00 and a low estimate of 128.00. The median estimate represents a 41.13% increase from the last price of 120.46.
High | 69.4% | 204.00 |
Med | 41.1% | 170.00 |
Low | 6.3% | 128.00 |
Earnings history & estimates in USD
The next earnings announcement is expected on Oct 29, 2024.
Average growth rate | +10.27% |
Average growth rate | +254.17% |
More ▼
Revenue history & estimates in USD
Average growth rate | +7.01% |
Average growth rate | +24.80% |
More ▼